Bazis Pharma reports positive Phase 1b clinical trial results for Gemini in CKD patients.

Bazis Pharmaceuticals has met its primary corporate objectives in 2025, including conducting a Phase 1b clinical study in CKD patients that demonstrated Gemini's ability to rebalance cellular inflammation. The company is in a good financial position and will continue to advance Gemini for both acute and chronic active inflammation treatment.